Carnitor® Tablets, Oral Solution, Sugar-Free Oral-Solution and Injection Correct Secondary Carnitine Deficiency That Can Occur With:

• Inborn Errors of Metabolism
• Other Iatrogenic Factors/Medical Conditions Such as:
• Valproate Therapy
• Antiretroviral Therapy and HIV
• Prematurity

Carnitor® Tablets, Oral Solution, Sugar-Free Oral Solution and Injection Are Effective and Safe Treatments for Carnitine Deficiency

Dosing^1,2

Oral Solution and Tablets: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day. Dosage should start at 50 mg/kg/day. See full Prescribing Information for detailed dosage and administration.

IV: The recommended dose for metabolic disorders is 50 mg/kg given as a slow 2 to 3 minute bolus injection or by infusion. See full Prescribing Information for detailed dosage and administration.

Safety^1,2

Adverse events reported with Carnitor® use include nausea, vomiting, body odor, gastritis, and seizures. There are no reported contraindications or warnings. See Precautions in the Prescribing Information.

Carnitor® therapy is appropriate in³ :

• Specific inborn errors of metabolism resulting in carnitine deficiency, including organic acid and fatty acid oxidation disorders
• Acquired medical conditions and iatrogenic factors resulting in carnitine deficiency:
• Extreme prematurity
• Chronic total parenteral nutrition (TPN)
• Malabsorption (cystic fibrosis and short-gut syndrome)
• Dietary deficiency
• Carnitine-deficient mothers
• Fanconi syndrome
• Certain medications, including valproic acid

References: 1. Carnitor® (levocarnitine) Tablets and Oral Solution, and Carnitor® SF Sugar-Free Oral Solution package insert. 2. Carnitor® (levocarnitine) Injection package insert. 3. De Vivo DC, Tein I: Primary and secondary disorders of carnitine metabolism. Int Pediatr 1990;5:134-141.